<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="16856">Glutathione</z:chebi> transferase (GST) activity and GST isoenzyme composition have been determined for 24 human <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and 6 human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>Substantial activity (40-1010 milliunits/mg protein) was identified in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens examined and three of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Three <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, the human small cell <z:mp ids='MP_0002038'>carcinoma</z:mp> line SW2-10S, the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> derived cell line Raji, and the human <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> cell line MCF-7, contained minimal GST activity </plain></SENT>
<SENT sid="3" pm="."><plain>Although the small size of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples precluded isoenzyme analysis by substrate specificities, analysis of GST activity following sample separation by isoelectric focusing indicated that the predominant (comprising at least 70% of the <z:chebi fb="0" ids="34718">1-chloro-2,4-dinitrobenzene</z:chebi>-conjugating activity) GST isoenzyme in each of these <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> (17 of 17) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell line (3 of 3) extracts was anionic (isoelectric point, 4.5-4.8) </plain></SENT>
<SENT sid="4" pm="."><plain>In three <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples, <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the lung, colon, and stomach, analysis by isoelectric focusing identified minor but detectable (10-20% of total) cationic GST </plain></SENT>
<SENT sid="5" pm="."><plain>The anionic form of GST has been purified to homogeneity from three primary human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>: a <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo>; a <z:mpath ids='MPATH_365'>mesothelioma</z:mpath>; and a <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>GST from these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> consists of two subunits each of Mr 25,200 </plain></SENT>
<SENT sid="7" pm="."><plain>On Western blot analysis, antibodies raised against the anionic GST purified from <z:mpath ids='MPATH_365'>mesothelioma</z:mpath> detect protein of Mr approximately 25,000 in extracts of both <z:mpath ids='MPATH_458'>normal</z:mpath> kidney and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> containing anionic GST activity but not in extracts of human liver that did not contain detectable anionic activity </plain></SENT>
<SENT sid="8" pm="."><plain>The amino acid compositions of these proteins were quite similar to that previously described for GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> and the amino-terminal amino acid sequences for these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived isoenzymes are identical to one another and to that previously described for GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> from human placenta </plain></SENT>
<SENT sid="9" pm="."><plain>GST is a major enzymatic activity in many human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, comprising as much as 3% of the cytosolic protein of some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Anionic GST is the predominant form of <z:chebi fb="0" ids="16856">glutathione</z:chebi> transferase activity in many human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="11" pm="."><plain>In selected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples the predominant anionic GST isoenzyme has been identified as a member of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> class of this enzyme family </plain></SENT>
<SENT sid="12" pm="."><plain>In addition, at least 3 of 17 tumor samples contained lesser but detectable amounts of cationic GST, probably of the alpha class </plain></SENT>
<SENT sid="13" pm="."><plain>By conjugating <z:chebi fb="0" ids="16856">glutathione</z:chebi> with electrophilic anticancer drugs, the substantial levels of GST in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> may have a role in the innate or acquired resistance of these <z:hpo ids='HP_0002664'>neoplasms</z:hpo> to anticancer therapy </plain></SENT>
</text></document>